Cabergoline is marketed primarily as Dostinex. Cabergoline is a relatively new pharmaceutical that has enormous potential aiding male stamina. The most remarkable aspect of carbergoline aka Dostinex is that it has been found to substantially increase a man’s chances of sustaining multiple orgasms during sex. Many men on cabergoline have reported numerous multiple orgasms in rapid succession.
In one study of Cabergoline, sixty healthy male participants ages 22 to 31 on average needed a break of 19 minutes between lovemaking sessions. After taking Cabergoline they were able to have multiple orgasms within a few minutes. Medical psychologist Manfred Schedlowski was involved with the trials at Essen in Germany and stated that Cabergoline raised the libido to enable the male to orgasm again more quickly.
While Cabergoline aka Dostinex is known best for its sexual enhancement characteristics it has other uses as well. Cabergoline (brand names Dostinex and Cabaser), an ergot derivative, is a potent dopamine receptor agonist on D2 receptors. In vitro, rat studies show cabergoline has a direct inhibitory effect onpituitary lactotroph (prolactin) cells. It is frequently used as a first-line agent in the management of prolactinomas due to higher affinity for D2 receptor sites, less severe side effects, and more convenient dosing schedule than the older bromocriptine. In less technical jargon Cabergoline lower prolactin levels. Excessive secretion of prolactin – which is known as hyperprolactinemia – is a relative common disorder in humans. Common symptoms of hyperprolactinemia in women can include menstrual irregularities, and galactorrhea (which was covered in the preceding paragraph). Sadly, men who have hyperprolactinemia tend to have most of the same symptoms; enlarged mammary glands, milk production, and also have some other side effects to contend with, such as hypogonadism, decreased libido (sex drive), decreased sperm production and impotence
There are many uses for Cabergoline and we will cover them in upcoming posts in this blog. Thank you for reading.
